Idebenone - debenone is a powerful antioxidant and positively affects brain chemistry
debenone is a powerful antioxidant and positively affects brain chemistry
debenone is a powerful antioxidant and positively affects brain chemistry.
Idebenone has been shown to promote information transfer across the corpus callosum, the membrane separating the right and left brain hemispheres.
Idebenone has been used to treat Alzheimer's and to lessen damage from strokes.
Idebenone increases nerve growth factor (NGF) in the brain.
Idebenone can increase production of the brain neurotransmitters serotonin, dopamine, adrenalin, and noradrenanlin.
Who can benefit from Idebenone
1. people desiring improved mental functioning.
2. Stroke victims.
3. Alzheimer's patients.
4. Those preparing for major surgery.
5. people with heart energetics problems, e.g. cardiomyopathy, congestive heart failure
6. people with myelination problems, e.g. multiple sclerosis.
7. Athletes with high endurance requirements such as marathoners, cyclists, etc
8. people wishing to enhance the brain serotonin benefits of SSRI's, (prozac, paxil)
9. Those suffering liver damage from toxic chemicals or hepatitis.
Weyer G, Babeji-Dolle RM, Hadler D, Hofmann S, Herrmann WM, " A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. " Neuropsychobiology 1997; 36(2):73-82
Ranen NG and colleagues, " A controlled trial of idebenone in Huntington's disease " Mov Disord 1996 Sep; 11(5):549-554
Ikejiri Y, Mori E, Ishii K, Yasuda M, Sasaki M, " Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS " Neurology 1996; Aug 47(2); 583-585.
pisano p and colleagues, " plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy ." Eur J pharmacol 1996; 51(2):167-169.
Gillis JC, Benefield p, McTavish D, " Idebenone, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders ." Drugs Aging 1994; Aug;5 (2): 133-152.
Bergamasco B, Scarzella L, " Idebenone, a new drug in the treatment of cognitive impariment in patients with dementia of the Alzheimer type ." Funct Neurol 1994; May;9(3):161-168.
Nitta A, Hasegawa T, " Oral administration of idebenone, a stimulator of NGF synthesis recovers reduced NGF content in aged rat brain ." Neuosci Lett 1993 Dec 12; 163(2):219-222.
Suno M, Nagaoka A, " Inhibition of brain mitochondrial swelling by idebenone ." Arch Gerontol Geriatr 1989 May; 8(3):299-305.
Ihara Y, Namba S, Shiraba T, " Mitochondrial encephalomyopathy (MELAS), pathological study and successful therapy with coenzyme Q10 and idebenone ." J Neurol Sci 1989 May; 90(3):263-271.
Lerman-Sagie T, Rustin p, Lev D, " Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone ." J Inherit Metab Dis 2001 Feb;24(1):28-34.
Gutzmann H, Hadler D., " Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease:update on a 2-year double-blind multicentre study ." J Neural Transm Suppl 1998;54:301-10.
Yamada K, Nitta A, Hasegawa T, " Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. " Behav Brain Res 1997 Feb;83(1-2):117-22.